Novartis Finance Corporation

Bausch + Lomb Ireland Limited, a subsidiary of Bausch + Lomb Corporation, has agreed to acquire Xiidra and other ophthalmology assets from Novartis for $1.75 billion in cash at closing, plus up to $750 million in milestone payments. The transaction is expected to close by end of 2023.